Cyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025

Reuters

08/27

<a href="https://laohu8.com/S/CYTH">Cyclo Therapeutics</a>, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025

Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, has had two abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. These presentations will focus on the use of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1. An oral presentation by Dr. Caroline Hastings will discuss the long-term efficacy and safety of Hydroxypropyl-beta-cyclodextrin, while a poster presentation by Dr. Orna Staretz Chacham will cover open-label treatment in young patients under the TransportNPC Sub-Study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518663-en) on August 27, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562285745"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562285745\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562285745?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-27 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562285745","market":"nz","top_or_hot":-1,"title":"Cyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CYTH\">Cyclo Therapeutics</a>, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RFL\">Rafael Holdings, Inc.</a> announced that its subsidiary, Cyclo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, has had two abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. These presentations will focus on the use of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1. An oral presentation by Dr. Caroline Hastings will discuss the long-term efficacy and safety of Hydroxypropyl-beta-cyclodextrin, while a poster presentation by Dr. Orna Staretz Chacham will cover open-label treatment in young patients under the TransportNPC Sub-Study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518663-en) on August 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-27 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CYTH\">Cyclo Therapeutics</a>, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RFL\">Rafael Holdings, Inc.</a> announced that its subsidiary, Cyclo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, has had two abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. These presentations will focus on the use of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1. An oral presentation by Dr. Caroline Hastings will discuss the long-term efficacy and safety of Hydroxypropyl-beta-cyclodextrin, while a poster presentation by Dr. Orna Staretz Chacham will cover open-label treatment in young patients under the TransportNPC Sub-Study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518663-en) on August 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL4xgrBT:1","article_id":"2562285745","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562285745","pubTimestamp":1756296038,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, has had two abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism  in Kyoto, Japan. These presentations will focus on the use of Trappsol Cyclo for treating Niemann-Pick Disease Type C1. An oral presentation by Dr. Caroline Hastings will discuss the long-term efficacy and safety of Hydroxypropyl-beta-cyclodextrin, while a poster presentation by Dr. Orna Staretz Chacham will cover open-label treatment in young patients under the TransportNPC Sub-Study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on August 27, 202","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Rafael Holdings子公司Cyclo Therapeutics将在ICIEM 2025上展示尼曼-皮克病研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RFL":0.9},"content_text":"Cyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025\n    \n\nRafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, has had two abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. These presentations will focus on the use of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1. An oral presentation by Dr. Caroline Hastings will discuss the long-term efficacy and safety of Hydroxypropyl-beta-cyclodextrin, while a poster presentation by Dr. Orna Staretz Chacham will cover open-label treatment in young patients under the TransportNPC Sub-Study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518663-en) on August 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}